Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Nippon Zoki, Teikoku Seiyaku to Codevelop Adhesive Agent for PHN
June 6, 2011
- Daiichi Sankyo Aims for Sales of ¥40 Bil. in China
June 6, 2011
- HPV Vaccine Gardasil Recommended for Approval
June 6, 2011
- ¥45.5 Billion Worth of New-type Flu Vaccines Discarded: Health Minister Hosokawa
June 6, 2011
- Astellas Looking for Partner for Global Development of Darexaban
June 6, 2011
- ASKA's Emergency Pill Priced at ¥10,000/Dose
June 6, 2011
- Teijin Pharma to Collect More Evidence on Efficacy of Feburic for Hyperuricemia
June 6, 2011
- JPA Opposes Drug Price Revision without Revision of Medical, Nursing Fees
June 6, 2011
- Santen Regains Top Spot in Domestic Glaucoma Market
June 6, 2011
- Sitagliptin Approved for Combination Therapy with αGI: MSD, Ono
June 6, 2011
- Seikagaku Preparing to Launch Gel-One in US Despite Patent Dispute
June 6, 2011
- Pfizer Files Simultaneous Application for Crizotinib in the US, Japan
June 6, 2011
- Kyorin HD: Double-Digit Growth in Sales, Profits Driven by Kipres
June 6, 2011
- Chugai Applies for Pediatric Use, Dosage of CellCept
June 6, 2011
- Kaken: Operating Profits Up 20%
June 6, 2011
- BM Files for Breast Cancer for Paraplatin Based on Public Knowledge
June 6, 2011
- Mochida: Net Profits Down 46% due to Earthquake
June 6, 2011
- Korosho Designates Velaglucerase Alfa as Orphan Drug for Gaucher's Disease
June 6, 2011
- Kissei: Sales Up 3.6% Driven by Major Products Including Urief
June 6, 2011
- 17 Companies to List Actos Generics in June, 9 to Delay Listing
June 6, 2011
ページ
Japan’s biotech startups are coming under growing pressure as the Tokyo Stock Exchange (TSE) tightens its rules for companies listed…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…